Disease management of Prader-Willi syndrome

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Prader-Willi Syndrome (PWS), first described in 1956, is a unique genetic condition with a prevalence of 1 in 10,000 - 25,000. Features include severe life-long hypotonia, insatiable appetite, short stature, obsessive-compulsive behaviour, morbid obesity, hypogonadism, kyphosis, scoliosis and osteoporosis. Studies beginning in the 1970s demonstrated that PWS is associated with a deficiency in growth hormone. Growth hormone treatment in children with PWS improves linear growth and more importantly leads to an increased muscle mass, bone mineral density and physical performance. In mid-2000, growth hormone became the first pharmaceutical approved in the US and Europe for the treatment of childhood PWS. It is now considered an essential part of comprehensive care for this condition. Ongoing studies address issues of growth hormone dosage, long-term efficacy, effects on neonatal and childhood growth and development and effects in adults with PWS.

Original languageEnglish (US)
Pages (from-to)1451-1459
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume3
Issue number10
DOIs
StatePublished - Oct 1 2002
Externally publishedYes

Fingerprint

Prader-Willi Syndrome
Disease Management
Growth Hormone
Compulsive Behavior
Obsessive Behavior
Kyphosis
Muscle Hypotonia
Hypogonadism
Morbid Obesity
Scoliosis
Appetite
Growth and Development
Bone Density
Osteoporosis
Muscles
Therapeutics
Growth
Pharmaceutical Preparations

Keywords

  • Body composition
  • Growth hormone
  • Hyperphagia
  • Insulin-like growth factor
  • obesity
  • Prader-Willi syndrome

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Disease management of Prader-Willi syndrome. / Lee, Phillip.

In: Expert Opinion on Pharmacotherapy, Vol. 3, No. 10, 01.10.2002, p. 1451-1459.

Research output: Contribution to journalArticle

@article{75c5a02756784575ae5e3214f82f424a,
title = "Disease management of Prader-Willi syndrome",
abstract = "Prader-Willi Syndrome (PWS), first described in 1956, is a unique genetic condition with a prevalence of 1 in 10,000 - 25,000. Features include severe life-long hypotonia, insatiable appetite, short stature, obsessive-compulsive behaviour, morbid obesity, hypogonadism, kyphosis, scoliosis and osteoporosis. Studies beginning in the 1970s demonstrated that PWS is associated with a deficiency in growth hormone. Growth hormone treatment in children with PWS improves linear growth and more importantly leads to an increased muscle mass, bone mineral density and physical performance. In mid-2000, growth hormone became the first pharmaceutical approved in the US and Europe for the treatment of childhood PWS. It is now considered an essential part of comprehensive care for this condition. Ongoing studies address issues of growth hormone dosage, long-term efficacy, effects on neonatal and childhood growth and development and effects in adults with PWS.",
keywords = "Body composition, Growth hormone, Hyperphagia, Insulin-like growth factor, obesity, Prader-Willi syndrome",
author = "Phillip Lee",
year = "2002",
month = "10",
day = "1",
doi = "10.1517/14656566.3.10.1451",
language = "English (US)",
volume = "3",
pages = "1451--1459",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Disease management of Prader-Willi syndrome

AU - Lee, Phillip

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Prader-Willi Syndrome (PWS), first described in 1956, is a unique genetic condition with a prevalence of 1 in 10,000 - 25,000. Features include severe life-long hypotonia, insatiable appetite, short stature, obsessive-compulsive behaviour, morbid obesity, hypogonadism, kyphosis, scoliosis and osteoporosis. Studies beginning in the 1970s demonstrated that PWS is associated with a deficiency in growth hormone. Growth hormone treatment in children with PWS improves linear growth and more importantly leads to an increased muscle mass, bone mineral density and physical performance. In mid-2000, growth hormone became the first pharmaceutical approved in the US and Europe for the treatment of childhood PWS. It is now considered an essential part of comprehensive care for this condition. Ongoing studies address issues of growth hormone dosage, long-term efficacy, effects on neonatal and childhood growth and development and effects in adults with PWS.

AB - Prader-Willi Syndrome (PWS), first described in 1956, is a unique genetic condition with a prevalence of 1 in 10,000 - 25,000. Features include severe life-long hypotonia, insatiable appetite, short stature, obsessive-compulsive behaviour, morbid obesity, hypogonadism, kyphosis, scoliosis and osteoporosis. Studies beginning in the 1970s demonstrated that PWS is associated with a deficiency in growth hormone. Growth hormone treatment in children with PWS improves linear growth and more importantly leads to an increased muscle mass, bone mineral density and physical performance. In mid-2000, growth hormone became the first pharmaceutical approved in the US and Europe for the treatment of childhood PWS. It is now considered an essential part of comprehensive care for this condition. Ongoing studies address issues of growth hormone dosage, long-term efficacy, effects on neonatal and childhood growth and development and effects in adults with PWS.

KW - Body composition

KW - Growth hormone

KW - Hyperphagia

KW - Insulin-like growth factor

KW - obesity

KW - Prader-Willi syndrome

UR - http://www.scopus.com/inward/record.url?scp=0036796364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036796364&partnerID=8YFLogxK

U2 - 10.1517/14656566.3.10.1451

DO - 10.1517/14656566.3.10.1451

M3 - Article

C2 - 12387691

AN - SCOPUS:0036796364

VL - 3

SP - 1451

EP - 1459

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -